Standout Papers

Phase II Trial of Gefitin... 2003 2026 2010 2018 2003 100 200 300 400 500
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation benchmark for papers published in the same subfield and year, or reaches the top citation threshold in at least one of its specific research topics.

  1. Phase II Trial of Gefitinib in Recurrent Glioblastoma
    2003 558 citations Jeremy N. Rich, David A. Reardon et al. Journal of Clinical Oncology profile →

Immediate Impact

1 by Nobel laureates 24 from Science/Nature 77 hit
Sub-graph 1 of 22

Citing Papers

Pharmacological treatment of hyperglycemia in type 2 diabetes
2021 Hit
Adipogenesis and metabolic health
2019 Hit

Works of Sandra Tourt-Uhlig being referenced

Results of a reevaluation of cardiovascular outcomes in the RECORD trial
2013
Methodology of a reevaluation of cardiovascular outcomes in the RECORD trial: Study design and conduct
2013

Author Peers

Peers are selected by citation overlap in the author's most active subfields. citations · hero ref

Author Last Decade Papers Cites
Sandra Tourt-Uhlig 807 507 359 269 233 12 1.3k
Hilary Blair 705 0.9× 430 0.8× 249 0.7× 169 0.6× 152 0.7× 17 1.2k
Genevieve Schindler 774 1.0× 604 1.2× 176 0.5× 231 0.9× 354 1.5× 8 1.3k
Jigisha P. Thakkar 685 0.8× 409 0.8× 407 1.1× 312 1.2× 136 0.6× 25 1.5k
Mackenzie Price 869 1.1× 411 0.8× 316 0.9× 194 0.7× 263 1.1× 22 1.5k
Britta Blaschke 653 0.8× 904 1.8× 253 0.7× 219 0.8× 221 0.9× 15 1.5k
Sandrine Ostermann 799 1.0× 539 1.1× 456 1.3× 304 1.1× 122 0.5× 22 1.7k
Corey Neff 941 1.2× 441 0.9× 359 1.0× 213 0.8× 282 1.2× 22 1.7k
David K. Lisle 1.1k 1.4× 464 0.9× 385 1.1× 124 0.5× 254 1.1× 12 1.4k
Mark Rosenblum 386 0.5× 474 0.9× 503 1.4× 283 1.1× 756 3.2× 17 1.8k
Leon Harisiadis 423 0.5× 218 0.4× 389 1.1× 213 0.8× 180 0.8× 18 1.2k

All Works

Loading papers...

Rankless by CCL
2026